Together, these therapeutic targets demonstrate how interventions directed at shared molecular pathways (NF-κB, NLRP3 inflammasome, IL-1β, IL-6/CRP axis) may yield synergistic benefits across DM, PD, and CVD, and should be prioritized in future translational trials. The gene discussed is CRP; the disease is diabetes mellitus.